Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies. Issue 9 (11th September 2019)

• Record Type: Journal Article
• Authors: Schwarting, Andreas; Möckel, Tamara; Lütgendorf, Freya; Triantafyllias, Konstantinos; Grella, Sophia; Boedecker, Simone; Weinmann, Arndt; Meineck, Myriam; Sommer, Clemens; Schermuly, Ingrid; Fellgiebel, Andreas; Luessi, Felix; Weinmann-Menke, Julia
• Is Part Of: Annals of the rheumatic diseases. Volume 78:Issue 9(2019)
• Page Start: 1226
• Publication Date: 2019-09-11
• Subjects: fatigue -- systemic lupus erythematosus -- anti-nmda receptor antibodies -- belimumab; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-215098
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: We explored the impact of circulating anti-N-methyl-D-aspartate receptor (NMDAR) antibodies on the severity of fatigue in patients with systemic lupus erythematosus (SLE). Methods: Serum samples of 426 patients with SLE were analysed for the presence of antibodies to the NR2 subunit of the NMDAR. In parallel, the severity of fatigue was determined according to the Fatigue Scale for Motor and Cognitive functions questionnaire. In a subgroup of patients with SLE, the hippocampal volume was correlated with the levels of anti-NR2 antibodies. Isolated immunoglobulin G from patients with anti-NR2 antibodies were used for murine immunohistochemical experiments and functional assays on neuronal cell lines. Treatment effects were studied in 86 patients with lupus under belimumab therapy. Results: We found a close correlation between the titre of anti-NR2 antibodies, the severity of fatigue, the clinical disease activity index (Systemic Lupus Erythematosus Disease Activity Index 2000) and anti-double stranded DNA antibodies—independently of the presence of neuropsychiatric lupus manifestations. Pathogenic effects could be demonstrated by (1) detection of anti-NR2 antibodies in the cerebrospinal fluid, (2) in situ binding of anti-NR2 antibodies to NMDAR of the hippocampus area and (3) distinct functional effects in vitro: downregulating the energy metabolism of neuronal cells without enhanced cytotoxicity. Treatment with belimumab for at least 6 months affected both the severity of fatigue and the levels of anti-NR2 antibodies. Conclusion: The presence of anti-NR2 antibodies in patients with SLE with fatigue is a helpful diagnostic tool and may offer a major approach in the therapeutic management of this important disabling symptom in patients with SLE.